Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease‐Modifying Antirheumatic Drug
Main finding · CDAI MID achievedResult — go to the resultOdds ratio 2.31 CI 1.79–2.99Authors' conclusion
PrismRA results informing selection of TNFi vs non-TNFi treatment was associated with better CDAI outcomes compared to matched external comparator patients.
Study context
- Population
- Patients with rheumatoid arthritis (RA) and moderate-high disease activity initiating a b/tsDMARDmatched cohort
- Participants
- 330 vs 990
- Exposure
- PrismRA-informed selection of tumor necrosis factor inhibitor (TNFi) vs non-TNFi vs matched external comparator patients
- PrismRAn = 330
- Comparatorn = 990reference
- Outcome
- Achievement of minimal important difference (MID) in clinical disease activity index (CDAI)
- Follow-up
- 24 weeks
Methodological detailslast observation carried forward imputation
- Last observation carried forward imputation
Main finding
CDAI MID achieved
Odds ratio
2.31
CI 1.79–2.99
By group
PrismRAvs Comparator
OR 2.31 (CI 1.79–2.99)
As reported in the abstract
Observational data: associations, not effects.
Further findings
- Study treatment selection consistent with PrismRA results
- 82%
Original publication
Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease‐Modifying Antirheumatic Drug. Arthritis Care Res (Hoboken). Published 2 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →